Observational studyArchivos de cardiologia de Mexico2026
Influence of socioeconomic status on ST-segment elevation myocardial infarction in Mexico.
Observational study in Archivos de cardiologia de Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn different countries, the impact of the socioeconomic status (SES) associated with different cardiovascular risk factors, incidence, and outcomes, including mortality, has been described. The objective was to determine the in-hospital survival in patients with ST-segment elevation myocardial infarction (STEMI) treated with a pharmacoinvasive strategy according to their SES.
methodA retrospective, unicentric, cohort-type observational study was carried out, involving 694 patients diagnosed with STEMI from March 2018 to April 2022 treated with a pharmacoinvasive strategy.
resultsThe study population was young, with an average age of 58 years. Systemic arterial hypertension, smoking, and diabetes were the most prevalent risk factors in the population regardless of SES. Chronic kidney disease was more prevalent in the SES ≥ 2 group. There were no differences in mortality; the total ischemic time was an average of 5 hours for both groups. There were no significant differences in the times and final outcomes of pharmacoinvasive therapy, with percentiles 25-75 of 6.9 to 48 h, and with a success rate of 62.7%.
conclusionsThe SES does not have an influence on the characteristics of the population and immediate outcomes, which is consistent with reports from countries with universal healthcare services, unlike countries with greater healthcare system restrictions due to the use of insurers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.